IL1A and disease arising from reactivation of latent virus: Nonetheless, given the elevated risk of infection associated with IL-1 blockers, it is recommended that thorough assessments be conducted for active and latent infections before initiating treatment, and that indicators of infection are closely monitored during therapy to minimize the risk of severe infectious events.